• Explore /
  • Poster
  • / Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Abstract Poster

Authors

null

Gwenael Ferron

GINECO and Institut Claudius Regaud, Toulouse, France

Gwenael Ferron , Gaetan De Rauglaudre , Annick Chevalier , Pierre Combe , Florence Joly , Alain Lortholary , Nadia Raban , Salima Hamizi , Emmanuelle Malaurie , Marie-Christine Kaminsky , Patricia Pautier , Jérome Meunier , Jérôme Alexandre , Dominique Berton-Rigaud , Anne Floquet , Laurence Venat-Bouvet , Laure Favier , Nadine Dohollou , Coraline Dubot , Isabelle Laure Ray-Coquard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

2011-006288-23

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5512)

DOI

10.1200/JCO.2019.37.15_suppl.5512

Abstract #

5512

Poster Bd #

335

Abstract Disclosures

Similar Posters

First Author: Patrick Robelin

First Author: Yolanda García

First Author: Claudio Zamagni

First Author: Claudia Marchetti